DE60144516D1 - Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie - Google Patents

Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie

Info

Publication number
DE60144516D1
DE60144516D1 DE60144516T DE60144516T DE60144516D1 DE 60144516 D1 DE60144516 D1 DE 60144516D1 DE 60144516 T DE60144516 T DE 60144516T DE 60144516 T DE60144516 T DE 60144516T DE 60144516 D1 DE60144516 D1 DE 60144516D1
Authority
DE
Germany
Prior art keywords
compositions
methods
immunostimulatory
dendritic cells
immunotherapy based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144516T
Other languages
German (de)
English (en)
Inventor
Reiner Laus
Damir Vidovic
Thomas Graddis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dendreon Corp
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Application granted granted Critical
Publication of DE60144516D1 publication Critical patent/DE60144516D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60144516T 2000-03-30 2001-03-30 Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie Expired - Lifetime DE60144516D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19350400P 2000-03-30 2000-03-30
PCT/US2001/010515 WO2001074855A2 (en) 2000-03-30 2001-03-30 Compositions and methods for dendritic cell-based immunotherapy

Publications (1)

Publication Number Publication Date
DE60144516D1 true DE60144516D1 (de) 2011-06-09

Family

ID=22713907

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60144516T Expired - Lifetime DE60144516D1 (de) 2000-03-30 2001-03-30 Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie

Country Status (13)

Country Link
US (2) US7060279B2 (https=)
EP (1) EP1272633B1 (https=)
JP (1) JP5110674B2 (https=)
AT (1) ATE507295T1 (https=)
AU (2) AU4791901A (https=)
CA (1) CA2403964C (https=)
CY (1) CY1111718T1 (https=)
DE (1) DE60144516D1 (https=)
DK (1) DK1272633T3 (https=)
ES (1) ES2362715T3 (https=)
NZ (1) NZ522066A (https=)
PT (1) PT1272633E (https=)
WO (1) WO2001074855A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
US7413869B2 (en) * 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
WO2003087338A2 (en) * 2002-04-11 2003-10-23 Amgen, Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
US7597894B2 (en) 2003-03-05 2009-10-06 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
WO2007147165A2 (en) * 2006-06-16 2007-12-21 Bresagen, Inc. Human cancer stem cell culture compositions comprising erbb2 variants and methods of use thereof
US7972602B2 (en) 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8309096B2 (en) 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
AR064863A1 (es) * 2007-01-15 2009-04-29 Glaxosmithkline Biolog Sa Proteina de fusion
JP2010532656A (ja) * 2007-01-15 2010-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 癌退縮抗原ｎｙ−ｅｓｏ−１およびｌａｇｅ−１を含む融合タンパク質
WO2008118369A2 (en) * 2007-03-22 2008-10-02 Dendreon Corporation Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
JP6426001B2 (ja) * 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
WO2017096247A1 (en) 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2048981B (en) * 1979-05-23 1982-11-17 Coal Ind Equipment for laying a layer of elongate material adjacent to an exposed rock or mineral surface in an underground mine
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5586538A (en) * 1995-11-13 1996-12-24 Caterpillar Inc. Method of correcting engine maps based on engine temperature
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
WO1998046769A1 (en) * 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
US6194152B1 (en) * 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
JP2002532514A (ja) * 1998-12-14 2002-10-02 デンドレオン コーポレイション 主要組織適合性複合体クラスｉ拘束抗原提示の増強のための、組成物および方法
HUP0105303A2 (en) * 1999-01-29 2002-05-29 Corixa Corp Her-2/neu fusion proteins
DE60014076T2 (de) * 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease

Also Published As

Publication number Publication date
EP1272633B1 (en) 2011-04-27
JP2003529608A (ja) 2003-10-07
US7659117B2 (en) 2010-02-09
ATE507295T1 (de) 2011-05-15
JP5110674B2 (ja) 2012-12-26
CY1111718T1 (el) 2015-10-07
ES2362715T3 (es) 2011-07-12
AU2001247919B2 (en) 2006-02-09
AU4791901A (en) 2001-10-15
DK1272633T3 (da) 2011-05-23
CA2403964A1 (en) 2001-10-11
CA2403964C (en) 2013-04-30
WO2001074855A2 (en) 2001-10-11
NZ522066A (en) 2004-08-27
PT1272633E (pt) 2011-06-27
EP1272633A2 (en) 2003-01-08
US7060279B2 (en) 2006-06-13
WO2001074855A3 (en) 2002-03-07
US20020061310A1 (en) 2002-05-23
US20050232932A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
DE60144516D1 (de) Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
DK0870022T3 (da) Immunstimulerende sammensætning og fremgangsmåde
Botarelli et al. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes
MXPA02010670A (es) Nuevas moleculas co-estimuladoras de celula dendritica.
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
WO2001029233A3 (en) Chimeric immunogenic compositions and nucleic acids encoding them
WO1999006544A8 (en) Membrane-bound cytokine compositions and methods of modulating an immune response using same
CA2290485A1 (en) Method for the production of non-immunogenic proteins
DK1002110T3 (da) Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
EP2196472A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CY1109710T1 (el) Επιτοπα βοηθητικων τ λεμφοκυτταρων
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
GB0113798D0 (en) Antigens and vectors for vaccination
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
BR0110394A (pt) Proteìna anti-congelamento, sequência nucleica, vetor, método para produzir uma proteìna anti-congelamento, organismo geneticamente modificado, extrato contendo proteìna, e, produto alimentìcio
WO2004026238A8 (en) Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
AU2363301A (en) Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes
ATE451618T1 (de) Verfahren zur identifizierung von epitopen in zusammenhang mit immunogenität bei biopharmazeutika
WO2003104263A3 (en) Cytokines and cytokine receptors with reduced immunogenicity
DE60130634D1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
DK0996636T3 (da) HA-1-antigenet
WO2004020592A3 (en) Retroductal salivary gland genetic vaccination